Selinexor for relapsed or refractory AML in combination treatments
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 3 trial studies selinexor (a medicine that changes signals inside cancer cells) used together with other leukemia treatment regimens for adults whose acute myeloid leukemia (AML) has come back or did not respond to standard therapy. It may help people reach remission or control the disease better than the current approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 60 years old
- Have AML that is either “refractory” (doesn’t respond) or “relapsed” (comes back) based on the trial’s timing and test rules
- Most people must have clear evidence of active bone marrow disease on a bone marrow scan (high activity or low production)
- Be able to do study tasks and clinic visits: physical status score (ECOG) must be 0–2
- Not have certain major conditions, like bleeding in the brain, pregnancy, serious heart rhythm problems, or an ECG QT interval over 500ms
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people age 55 and older with high-risk acute myeloid leukemia (AML) who have already had a stem cell transplant. It tests a new combination of two drugs, Selinexor and Melphalan, given twice a week to help prevent the leukemia from coming back.
This trial studies whether selinexor combined with azacitidine and venetoclax can treat newly diagnosed acute myeloid leukemia (AML) in people who may not be able to tolerate intensive chemotherapy. It’s aimed at improving leukemia control with a treatment approach designed for patients with higher risk from other health problems.
This trial tests a combination of two drugs, selinexor and azacitidine, for people with high-risk blood cancers like MDS, AML, or CMML, especially those who have leftover leukemia cells before a stem cell transplant. The goal is to see if this treatment can improve outcomes.
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
This trial tests a drug called selinexor to help shrink blood cell counts in patients with rare bone marrow disorders (polycythemia vera, essential thrombocythemia, or primary myelofibrosis) who cannot tolerate or are unwilling to use standard treatments. The goal is to reduce symptoms like extreme platelet counts, high white blood cell counts, or enlarged spleen.
This trial tests whether two drugs, Selinexor and Venetoclax, can help prevent leukemia or MDS from coming back after a stem cell transplant. It is for people who are at high risk of relapse and have recently had a transplant.
Hear when a new Relapsed or Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.